Latest insights on bacterial contamination in platelet concentrates

Cerus Websites

Sepsis Webinar Series: Part 1

Are you aware of the continuing risk of septic transfusion reactions?
We will bring you up to date with the latest, most relevant insights in a series of short educational webinars hosted by experts to cover three key subjects:

Latest insights on bacterial contamination in platelet concentrates

Introduction
Marcus Picard-Maureau | Scientific Affairs Director EMEA | Cerus Europe

Runtime: 9 minutes

You May Also Be Interested In

About Cerus

Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. In the US, the INTERCEPT Blood System for Cryoprecipitation is approved for the production of Pathogen Reduced Cryoprecipitated Fibrinogen Complex (commonly referred to as INTERCEPT Fibrinogen Complex), a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. The INTERCEPT red blood cell system is in late-stage clinical development. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.

Cerus.com

INTERCEPT-USA.com

HCP.INTERCEPT-USA.com

INTERCEPT-Canada.com

INTERCEPTBloodSystem.com

INTERCEPT-Cryoprecipitation.com

Sepsis Webinar Series: Part 1

Latest insights on bacterial contamination in platelet concentrates

You May Also Be Interested In

About Cerus